ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,037.59
1.06%
US Tech 100
21,156.38
-0.20%
다우존스 지수
43,325.80
0.07%
Bitcoin
95,565.46
-3.76%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Eloxx Pharmaceuticals Inc (ELOX)

  7. Eloxx Pharmaceuticals Inc (ELOX) 뉴스

ELOX

Eloxx Pharmaceuticals (ELOX)

Eloxx Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ELOX
일자시간출처헤드라인심볼기업
2024/08/2109:13Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ELOXEloxx Pharmaceuticals Inc
2024/07/1200:46GlobeNewswire Inc.Eloxx Pharmaceuticals Provides Pipeline and Financing UpdatesNASDAQ:ELOXEloxx Pharmaceuticals Inc
2024/04/1620:30GlobeNewswire Inc.Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program UpdatesNASDAQ:ELOXEloxx Pharmaceuticals Inc
2024/04/0205:02Edgar (US Regulatory)Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405NASDAQ:ELOXEloxx Pharmaceuticals Inc
2024/03/3005:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
2024/03/2203:20Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
2024/03/1505:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
2024/03/1400:42GlobeNewswire Inc.Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseasesNASDAQ:ELOXEloxx Pharmaceuticals Inc
2024/01/2706:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
2024/01/2706:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
2024/01/2706:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
2024/01/2706:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELOXEloxx Pharmaceuticals Inc
2024/01/2511:44Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELOXEloxx Pharmaceuticals Inc
2024/01/2507:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ELOXEloxx Pharmaceuticals Inc
2024/01/1007:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
2023/12/2906:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
2023/11/1406:15GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business UpdateNASDAQ:ELOXEloxx Pharmaceuticals Inc
2023/10/1706:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
2023/10/0921:00GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of ProteinuriaNASDAQ:ELOXEloxx Pharmaceuticals Inc
2023/09/2105:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
2023/09/2102:26Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ELOXEloxx Pharmaceuticals Inc
2023/09/1921:00GlobeNewswire Inc.Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:ELOXEloxx Pharmaceuticals Inc
2023/09/1821:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
2023/09/1820:00GlobeNewswire Inc.Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeNASDAQ:ELOXEloxx Pharmaceuticals Inc
2023/09/1606:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
2023/09/0723:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
2023/09/0722:00GlobeNewswire Inc.Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013NASDAQ:ELOXEloxx Pharmaceuticals Inc
2023/08/3005:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
2023/08/2205:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
2023/08/1500:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELOXEloxx Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:ELOX

최근 히스토리

NYSE
MCD
McDonalds
USOTC
DTEGY
Deutsche Telekom (QX)
AMEX
XLV
Health Care Select Sector
FX
USDEUR
US Dollar vs Euro
CCOM
US500
US 500
USOTC
RHHBY
Roche (QX)
AMEX
XLE
Energy Select Sector SPDR
AMEX
XLF
Financial Select Sector
NASDAQ
AAPL
Apple
COIN
AVAXUSD
Avalanche
NYSE
CVX
Chevron
NASDAQ
GOOGL
Alphabet
CCOM
US100
US Tech 100
NYSE
NKE
Nike
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유